Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration.
about
Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseasesImpacts of hypoxia-inducible factor-1 knockout in the retinal pigment epithelium on choroidal neovascularization.Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition.The role of the hypoxia response in shaping retinal vascular development in the absence of Norrin/Frizzled4 signaling.VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV.The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease.MEF2C ablation in endothelial cells reduces retinal vessel loss and suppresses pathologic retinal neovascularization in oxygen-induced retinopathySildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity.Balancing the risks and benefits of oxygen therapy in critically III adults.Prolyl 4-hydroxylases, master regulators of the hypoxia response.Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies.Blockade of vascular endothelial growth factor receptor 1 prevents inflammation and vascular leakage in diabetic retinopathy.The PHD1 oxygen sensor in health and disease.Diacylglycerol kinase (DGK) inhibitor II (R59949) could suppress retinal neovascularization and protect retinal astrocytes in an oxygen-induced retinopathy model.The progress of prophylactic treatment in retinopathy of prematurity.
P2860
Q28297656-9EC3F217-C331-4496-B623-0EC487AC47BAQ33960351-51C366C7-8909-4251-BC18-13733ACB60B3Q34762469-783CB830-1F0C-4DFE-B8E9-9C0046E690EDQ34795145-7E745BDE-D236-46C5-8F2E-1AB906726A57Q34972337-8DB7A5D9-A635-4B95-B145-AF34372F8E5BQ35807878-C2816DFA-C460-42DF-97E1-D2EDE9DF8F25Q36044670-50BDC907-B380-4A09-B67C-126F9D4DF36CQ36103389-3D8F988E-10D6-40A4-BBB6-72497D88B60FQ36740778-D7DD1704-16B9-404C-BAC1-87B28080C449Q38089239-8125F4A9-2BF3-4BF0-85E5-DCAA4D63ABE9Q41494887-06E6FD07-BB27-45AB-90FC-09E528FD54B6Q42123271-878B45A5-9CE6-429E-A0EC-DE1948E9A0F3Q50050250-4DE84412-81ED-410F-BFEA-3C3BF644D466Q54305745-7CEA227F-F73B-45A8-A73B-DDB0D3E6D2DFQ54999086-3E1DAC80-FF91-4AB2-AB65-A74C77DC43C3
P2860
Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reduced retinal neovasculariza ...... induced vascular obliteration.
@ast
Reduced retinal neovasculariza ...... induced vascular obliteration.
@en
type
label
Reduced retinal neovasculariza ...... induced vascular obliteration.
@ast
Reduced retinal neovasculariza ...... induced vascular obliteration.
@en
prefLabel
Reduced retinal neovasculariza ...... induced vascular obliteration.
@ast
Reduced retinal neovasculariza ...... induced vascular obliteration.
@en
P2093
P2860
P356
P1476
Reduced retinal neovasculariza ...... induced vascular obliteration.
@en
P2093
Mansi Dalal
Rachel Parlier
Sara Van de Veire
Stanley A Vinores
P2860
P304
P356
10.1167/IOVS.11-8002
P407
P577
2011-09-29T00:00:00Z